Fetal hemoglobin (HbF) is a form of hemoglobin that carries oxygen in a developing baby’s blood. After birth, the body gradually switches to producing adult hemoglobin, and by six months of age, adult hemoglobin is dominant. In healthy adults, fetal hemoglobin makes up less than 1% of total hemoglobin. When levels rise above about 2%, it can signal an inherited blood condition, a response to physiological stress, or in some cases, a natural genetic variation that turns out to be protective.
How the Body Switches From Fetal to Adult Hemoglobin
During pregnancy, fetal hemoglobin has a critical job: it binds oxygen more tightly than adult hemoglobin, allowing a baby to pull oxygen from the mother’s blood across the placenta. Once a baby is born and breathing on their own, that extra oxygen-grabbing ability is no longer needed.
Around the time of birth, the body begins silencing the gene responsible for fetal hemoglobin (the gamma-globin gene) and ramping up the gene for adult hemoglobin (beta-globin). This process involves two mechanisms working together: competition between the two genes for activation, and direct silencing of the fetal gene. By six months of age, adult hemoglobin is the dominant form circulating in the blood. The small trace of HbF that remains in adults, typically under 1%, reflects the fact that this silencing is very effective but not absolute.
What Counts as a Normal Level
A standard hemoglobin electrophoresis test, which separates different hemoglobin types by electrical charge, reports fetal hemoglobin as a percentage of total hemoglobin. For adults, a normal HbF reading falls between 0.8% and 2%. Anything above 2% is flagged for further evaluation. The test is commonly ordered alongside newborn screening, during workups for unexplained anemia, or when a blood disorder like sickle cell disease or thalassemia is suspected.
Genetic Reasons HbF Stays High
Some people carry mutations that prevent the fetal hemoglobin gene from fully shutting off. The best-known example is hereditary persistence of fetal hemoglobin (HPFH), a condition where HbF production continues well into adulthood at levels that can range from a few percent to over 30%. HPFH is caused by mutations within the beta-globin gene cluster or in the promoter region that controls the fetal hemoglobin gene. These mutations come in two broad types: deletions, where a stretch of DNA is missing, and point mutations, where a single letter in the genetic code is changed.
HPFH on its own is generally harmless. People with it often have no symptoms and may never know they carry it unless a blood test reveals elevated HbF. Where HPFH becomes medically significant is when it coexists with another hemoglobin disorder like sickle cell disease or beta-thalassemia, because the persistent fetal hemoglobin can offset some of the damage those conditions cause.
Non-Genetic Causes of Elevated HbF
Fetal hemoglobin can also rise temporarily in adults who don’t carry any inherited mutations. This typically happens when the bone marrow is under stress and producing red blood cells at an accelerated rate, a process called stress erythropoiesis. In that rush to make new cells, the body sometimes reactivates the fetal hemoglobin gene.
Situations that can trigger this include:
- Recovery from bone marrow suppression, such as after chemotherapy or a bone marrow transplant, when the marrow is rebuilding its cell supply quickly
- Pregnancy, when blood volume expands and red blood cell production increases
- Chronic hemolysis, conditions where red blood cells are being destroyed faster than normal, forcing the marrow to compensate
- Certain cancers, both blood-related malignancies and some solid tumors
In premature infants and babies born to mothers with diabetes, the switch from fetal to adult hemoglobin may simply be delayed rather than disrupted, leading to temporarily higher HbF levels that resolve on their own.
Why Fetal Hemoglobin Protects Against Sickling
In sickle cell disease, the abnormal hemoglobin (HbS) tends to clump into rigid chains when it releases oxygen, warping red blood cells into a stiff crescent shape. These sickled cells clog small blood vessels, causing intense pain episodes and organ damage. Fetal hemoglobin physically interferes with this clumping process. When enough HbF is present inside a red blood cell, it disrupts the chain formation that HbS molecules need to sickle.
This is why infants with sickle cell disease are typically symptom-free for the first several months of life: their blood still contains high levels of protective fetal hemoglobin. Symptoms begin as HbF drops and HbS takes over. The key detail is that the HbF needs to be present in high enough concentrations within each individual red blood cell to block sickling. A modest average HbF level spread unevenly across cells offers less protection than the same percentage distributed uniformly.
Treatments That Boost Fetal Hemoglobin
The protective power of fetal hemoglobin has made it a major therapeutic target for sickle cell disease and beta-thalassemia. The goal is essentially to reverse part of the hemoglobin switch, coaxing adult bone marrow into producing more HbF.
Hydroxyurea has been the standard approach for decades. It increases fetal hemoglobin production, though the exact mechanism isn’t fully understood. Beyond boosting HbF, it also appears to reduce inflammation, lower the stickiness of blood cells, and decrease the number of white blood cells that contribute to blood vessel blockages. For many patients with sickle cell disease, hydroxyurea significantly reduces pain crises and the need for blood transfusions.
Gene Editing Therapies
A newer and more dramatic approach uses CRISPR gene editing to permanently reactivate fetal hemoglobin. The target is a protein called BCL11A, which acts as the main “off switch” for the fetal hemoglobin gene in adult red blood cells. By editing a specific regulatory region of the BCL11A gene in a patient’s own blood stem cells, scientists can reduce its activity and allow fetal hemoglobin production to resume.
In early clinical trials published in the New England Journal of Medicine, patients with sickle cell disease and beta-thalassemia received their own edited stem cells after a course of chemotherapy to clear the existing bone marrow. The results were striking: both patients showed substantial, sustained increases in fetal hemoglobin that persisted for over a year. Fetal hemoglobin was distributed evenly across virtually all red blood cells, mimicking the natural pattern seen in people with hereditary persistence of fetal hemoglobin. The sickle cell patient had no further pain crises, and the thalassemia patient no longer needed blood transfusions. This therapy, now approved under the brand name Casgevy, essentially recreates the HPFH phenotype through precision gene editing.
What Elevated HbF Means for You
If a blood test shows your fetal hemoglobin is above 2%, the next step is usually figuring out whether the cause is genetic or acquired. A hemoglobin electrophoresis test can identify different hemoglobin types and their proportions, while genetic testing can look for specific mutations associated with HPFH or other hemoglobinopathies like thalassemia or sickle cell trait.
Context matters. If you’re recovering from chemotherapy, pregnant, or have a known condition that causes red blood cell destruction, mildly elevated HbF is expected and usually resolves once the underlying trigger settles. If there’s no obvious explanation and your levels are persistently high, genetic testing can determine whether you carry an HPFH variant. For carriers of sickle cell trait or thalassemia trait, knowing your HbF level provides useful information about how your condition may behave and what to consider in family planning.